1: Monn JA, Prieto L, Taboada L, Pedregal C, Hao J, Reinhard MR, Henry SS, Goldsmith PJ, Beadle CD, Walton L, Man T, Rudyk H, Clark B, Tupper D, Baker SR, Lamas C, Montero C, Marcos A, Blanco J, Bures M, Clawson DK, Atwell S, Lu F, Wang J, Russell M, Heinz BA, Wang X, Carter JH, Xiang C, Catlow JT, Swanson S, Sanger H, Broad LM, Johnson MP, Knopp KL, Simmons RM, Johnson BG, Shaw DB, McKinzie DL. Synthesis and pharmacological characterization of C4-disubstituted analogs of 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: identification of a potent, selective metabotropic glutamate receptor agonist and determination of agonist-bound human mGlu2 and mGlu3 amino terminal domain structures. J Med Chem. 2015 Feb 26;58(4):1776-94. doi: 10.1021/jm501612y. Epub 2015 Feb 5. PubMed PMID: 25602126.
2: Di Prisco S, Merega E, Bonfiglio T, Olivero G, Cervetto C, Grilli M, Usai C, Marchi M, Pittaluga A. Presynaptic, release-regulating mGlu2 -preferring and mGlu3 -preferring autoreceptors in CNS: pharmacological profiles and functional roles in demyelinating disease. Br J Pharmacol. 2016 May;173(9):1465-77. doi: 10.1111/bph.13442. Epub 2016 Mar 3. PubMed PMID: 26791341; PubMed Central PMCID: PMC4831303.
3: Sanger H, Hanna L, Colvin EM, Grubisha O, Ursu D, Heinz BA, Findlay JD, Vivier RG, Sher E, Lodge D, Monn JA, Broad LM. Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR. Neuropharmacology. 2013 Mar;66:264-73. doi: 10.1016/j.neuropharm.2012.05.023. Epub 2012 May 30. PubMed PMID: 22659090.